DB
Therapeutic Areas
Galapagos Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Jyseleca (filgotinib) | Rheumatoid Arthritis | Marketed |
| GLPG5201 | Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 1/2 |
| GLPG5101 | Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) | Phase 1/2 |
| Undisclosed T Cell Engager | Autoimmune Diseases | Discovery/Preclinical |
Leadership Team at Galapagos
HG
Henry Gosebruch
Executive Director and Chief Executive Officer
FB
Fred Blakeslee
General Counsel
AC
Aaron Cox
Chief Financial Officer
DG
Dan Grossman
Chief Strategy Officer
SK
Sooin Kwon
Chief Business Officer
JM
John Mellors
Head of Cell and Antibody Therapy Discovery
GP
Guy Peeters
Senior Vice President Finance
TP
Tania Philipp
Chief Human Resource Officer
JT
Jason Treese
Global Head of Quality Governance
JC
Jérôme Contamine
Chair of the Board, Non-Executive Independent Director